Catalent (CTLT) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall St set for lower open as AI jitters rekindle, oil gains
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Catalent, Inc. Reports Second Quarter 2016 Results
February 9, 2016 4:16 PM ESTRevenue in line with prior year as reported and increased 6% in constant currency to $454.9 million from second quarter 2015 Adjusted Net Income totaled $44.9 million, or $0.36 per diluted share Entered into a research collaboration with Roche to develop next generation molecules using Catalents proprietary SMARTag technology Announced a long-term exclusive agreement with Pfizer to produce Nexium® 24HR, its leading OTC heartburn medication
SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc. (NYSE:... More



